title: Potentiatied antitumor effectiveness of combined chemo-immunotherapy with interleukin-12 and 5-fluorouracil of L1210 leukemia in vivo.
abstract: In this study we investigated the efficacy of a combination of IL-12 and 5-FU, a chemotherapeutic exerting several immunomodulatory effects, in murine L1210 leukemia. Mice inoculated with 1 x 10(5) leukemia cells were treated with a single dose of 5-FU (50 mg/kg) and seven daily doses of IL-12 (100 ng/dose), and were observed for survival. Treatment with IL-12 or 5-FU given alone produced moderate anti-leukemic effects. However, combination of both drugs resulted in a significant prolongation of mouse survival time. Importantly, there were 70% of long-term (>60 days) survivors among mice treated with both agents simultaneously. Moreover, we observed 100% of long-term survivors when mice were treated with a minimally increased dose of IL-12 (170 ng) in combination with 5-FU (50 mg/kg). The antileukemic effects were completely abrogated in scid/scid mice and in mice depleted of peritoneal macrophages and significantly decreased after administration of anti-CD3+, anti-CD4+ or anti-CD8+ monoclonal antibodies. Administration of anti-NK1.1 antibodies did not decrease the antileukemic effects indicating that NK cells are not important effectors of this treatment regimen. Collectively, these results indicate that the combination of IL-12 and 5-FU is inducing strong antileukemic responses that are dependent on the presence and activity of macrophages and T lymphocytes and warrant further studies of combined chemo-immunotherapy with IL-12.
authors.affiliation: Department of Immunology, Center of Biostructsure Research, Medical University of Warsaw, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Goł b
authors.forename: R
authors.initials: R
authors.lastname: Zagozdzon
authors.forename: R
authors.initials: R
authors.lastname: Kamiński
authors.forename: K
authors.initials: K
authors.lastname: Kozar
authors.forename: K
authors.initials: K
authors.lastname: Gryska
authors.forename: D
authors.initials: D
authors.lastname: Izycki
authors.forename: A
authors.initials: A
authors.lastname: Mackiewicz
authors.forename: T
authors.initials: T
authors.lastname: Stokłosa
authors.forename: A
authors.initials: A
authors.lastname: Giermasz
authors.forename: W
authors.initials: W
authors.lastname: Lasek
authors.forename: M
authors.initials: M
authors.lastname: Jakóbisiak
mesh_terms: D000818:Animals; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D007371:Interferon-gamma / Q000097:blood; D018664:Interleukin-12 / Q000008:administration & dosage*; D007694:Killer Cells, Natural / Q000276:immunology; D007939:Leukemia L1210 / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D008264:Macrophages / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D016513:Mice, SCID
chemical_list: D018664:Interleukin-12; D007371:Interferon-gamma; D005472:Fluorouracil